Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
10 2023
Historique:
received: 17 03 2023
revised: 13 06 2023
accepted: 17 07 2023
medline: 11 9 2023
pubmed: 29 7 2023
entrez: 28 7 2023
Statut: ppublish

Résumé

Previous work found that during the first wave of the COVID-19 pandemic, 34% of patients with lung cancer treated with curative-intent radiotherapy in the UK had a change to their centre's usual standard of care treatment (Banfill et al. Clin Oncol 2022;34:19-27). We present the impact of these changes on patient outcomes. The COVID-RT Lung database was a prospective multicentre UK cohort study including patients with stage I-III lung cancer referred for and/or treated with radical radiotherapy between April and October 2020. Data were collected on patient demographics, radiotherapy and systemic treatments, toxicity, relapse and death. Multivariable Cox and logistic regression were used to assess the impact of having a change to radiotherapy on survival, distant relapse and grade ≥3 acute toxicity. The impact of omitting chemotherapy on survival and relapse was assessed using multivariable Cox regression. Patient and follow-up forms were available for 1280 patients. Seven hundred and sixty-five (59.8%) patients were aged over 70 years and 603 (47.1%) were female. The median follow-up was 213 days (119, 376). Patients with stage I-II non-small cell lung cancer (NSCLC) who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.859) or death (P = 0.884); however, they did have increased odds of grade ≥3 acute toxicity (P = 0.0348). Patients with stage III NSCLC who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.216) or death (P = 0.789); however, they did have increased odds of grade ≥3 acute toxicity (P < 0.001). Patients with stage III NSCLC who had their chemotherapy omitted had no significant increase in distant relapse (P = 0.0827) or death (P = 0.0661). This study suggests that changes to radiotherapy and chemotherapy made in response to the COVID-19 pandemic did not significantly affect distant relapse or survival. Changes to radiotherapy, namely increased hypofractionation, led to increased odds of grade ≥3 acute toxicity. These results are important, as hypofractionated treatments can help to reduce hospital attendances in the context of potential future emergency situations.

Identifiants

pubmed: 37507280
pii: S0936-6555(23)00263-7
doi: 10.1016/j.clon.2023.07.005
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e593-e600

Subventions

Organisme : Department of Health
ID : BRC-1215-20007
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C147/A18083
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C147/ A25254
Pays : United Kingdom

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Auteurs

I Fornacon-Wood (I)

University of Manchester, Manchester, UK. Electronic address: Isabella.fornacon-wood@postgrad.manchester.ac.uk.

K Banfill (K)

University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.

S Ahmad (S)

Guy's and St Thomas' NHS Foundation Trust, London, UK.

A Britten (A)

Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.

C Carson (C)

The Northern Ireland Cancer Centre, Belfast, UK.

N Dorey (N)

Torbay and South Devon NHS Foundation Trust, Torquay, UK.

M Hatton (M)

Weston Park Hospital, Sheffield, UK.

C Hiley (C)

University College London Hospitals, London, UK.

K Thippu Jayaprakash (K)

Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

A Jegannathen (A)

University Hospitals North Midlands, Stoke on Trent, UK.

A C Kidd (AC)

Singleton Hospital, Swansea, UK.

P Koh (P)

Royal Wolverhampton NHS Trust, Wolverhampton, UK.

N Panakis (N)

Oxford University Hospitals NHS Trust, Oxford, UK.

C Peedell (C)

The James Cook University Hospital, Middlesborough, UK.

A Peters (A)

Beatson West of Scotland Cancer Centre, Glasgow, UK.

A Pope (A)

Clatterbridge Cancer Centre, Liverpool, UK.

C Powell (C)

Velindre Cancer Centre, Cardiff, UK.

C Stilwell (C)

Aberdeen Royal Infirmary, Aberdeen, UK.

B Thomas (B)

Swansea Bay University Hospital, Swansea, UK.

E Toy (E)

Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

K Wicks (K)

University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.

V Wood (V)

University Hospitals Southampton NHS Foundation Trust, Southampton, UK.

S Yahya (S)

University Hospitals Birmingham, Birmingham, UK.

G Price (G)

University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.

C Faivre-Finn (C)

University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH